Guardant Health has launched the Guardant Reveal liquid biopsy test to detect residual cancer cells and the possibility of recurrence in patients with early-stage colorectal cancer.

The recently approved liquid biopsy tests show great potential in helping to diagnose and plan effective treatment for cancer.

Both men and women can develop breast cancer with a low percentage of men, less than 1%. In fact, men often pay less attention to abnormal changes in the breast and are often diagnosed with breast cancer at a later stage than women. Early recognition and diagnosis help reduce mortality, reduce complications, and improve treatment effectiveness.

Cancer biopsy test is an important test that is very valuable in effective cancer diagnosis and screening. This is a simple method but gives highly accurate results to prevent life-threatening risks.